Harvard Bioscience, Inc.

General ticker "HBIO" information:

  • Sector: Health Care
  • Industry: Life Sciences Tools & Services
  • Capitalization: $99.7M (TTM average)

Harvard Bioscience, Inc. follows the US Stock Market performance with the rate: 2.5%.

Estimated limits based on current volatility of 5.4%: low 0.30$, high 0.33$

Factors to consider:

  • China accounted for 14.1% of revenue in the fiscal year ended 2024-12-31
  • US accounted for 44.3% of revenue in the fiscal year ended 2024-12-31
  • Current price 81.5% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [1.62$, 3.22$]
  • 2025-12-31 to 2026-12-31 estimated range: [1.30$, 2.69$]

Financial Metrics affecting the HBIO estimates:

  • Negative: Non-GAAP EPS, $ of 0.03 <= 0.04
  • Negative: Operating cash flow per share per price, % of 1.51 <= 1.79
  • Positive: Industry inventory ratio change (median), % of -0.30 <= -0.28
  • Negative: negative Net income
  • Negative: negative Operating income
  • Positive: Investing cash flow per share, $ of -0.03 > -0.09
  • Positive: 43.26 < Shareholder equity ratio, % of 50.01 <= 63.75
  • Negative: Industry operating cash flow per share per price (median), % of 0.98 <= 2.82
  • Negative: negative Industry operating income (median)

Similar symbols

Short-term HBIO quotes

2025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-022025-05-052025-05-062025-05-070.30.350.40.450.50.550.60.65
Price $

Long-term HBIO plot with estimates

02468Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 202700.05
HBIOS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $113.33MM $112.25MM $94.14MM
Operating Expenses $120.27MM $110.36MM $100.35MM
Operating Income $-6.93MM $1.89MM $-6.21MM
Non-Operating Income $-2.25MM $-4.45MM $-5.45MM
Interest Expense $2.55MM $3.59MM $3.21MM
R&D Expense $12.33MM $11.76MM $10.41MM
Income(Loss) $-9.18MM $-2.56MM $-11.66MM
Taxes $0.34MM $0.86MM $0.74MM
Profit(Loss)* $-9.52MM $-3.42MM $-12.40MM
Stockholders Equity $72.22MM $73.07MM $63.34MM
Inventory $26.44MM $24.72MM $23.25MM
Assets $145.36MM $137.37MM $126.64MM
Operating Cash Flow $1.15MM $14.03MM $1.44MM
Capital expenditure $1.59MM $2.31MM $2.64MM
Investing Cash Flow $-1.59MM $-1.80MM $-1.34MM
Financing Cash Flow $-2.84MM $-12.13MM $-0.13MM
Earnings Per Share** $-0.23 $-0.08 $-0.28

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.